Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Average Price Target of $10.00 According to Analysts

by · The Cerbat Gem

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.00.

Several research analysts recently issued reports on ATHE shares. LADENBURG THALM/SH SH initiated coverage on shares of Alterity Therapeutics in a research report on Tuesday, June 16th. They issued a “buy” rating and a $10.00 target price for the company. Lake Street Capital assumed coverage on Alterity Therapeutics in a research note on Tuesday, September 15th. They set a “buy” rating and a $10.00 price target for the company. Craig Hallum set a $2.00 price objective on Alterity Therapeutics in a research report on Tuesday, August 11th. Zacks Research raised Alterity Therapeutics to a “hold” rating in a report on Wednesday, June 17th. Finally, JonesTrading initiated coverage on Alterity Therapeutics in a research report on Tuesday, June 30th. They issued a “buy” rating and a $16.00 target price for the company.

Read Our Latest Research Report on Alterity Therapeutics

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Alterity Therapeutics stock. Greenleaf Trust increased its holdings in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Free Report) by 93.8% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 62,000 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Greenleaf Trust owned approximately 0.70% of Alterity Therapeutics worth $333,000 as of its most recent SEC filing. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Trading Down 1.1%

Shares of Alterity Therapeutics stock opened at $3.45 on Wednesday. Alterity Therapeutics has a 1 year low of $2.66 and a 1 year high of $5.89. The company has a 50 day simple moving average of $4.28 and a two-hundred day simple moving average of $4.34.

Alterity Therapeutics (NASDAQ:ATHE – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.28) EPS for the quarter. The firm had revenue of $0.31 million for the quarter. As a group, equities research analysts expect that Alterity Therapeutics will post -0.12 EPS for the current year.

About Alterity Therapeutics

(Get Free Report)

Alterity Therapeutics Limited (NASDAQ: ATHE) is an Australia-based clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on abnormal protein misfolding and aggregation, biological processes associated with disorders such as multiple system atrophy and Parkinson’s disease.

The company’s lead drug candidate, ATH-434, is an orally administered small molecule designed to cross the blood-brain barrier and inhibit the aggregation of alpha-synuclein, a protein implicated in several neurodegenerative conditions.

Featured Stories